---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence. Covers CAPTIVATE and DNTH103-AU-001. 126 evidence topics quoted from 34 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 CAPTIVATE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).”
> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.1-2"></a>

###### Primary objective stated by the investigators

> “The primary objective of CAPTIVATE is to evaluate the efficacy of claseprubart compared to placebo, assessed as the time from first dose in Part B to relapse (≥1 point increase in adjusted INCAT) (Table 1).”
> “Safety and tolerability will be assessed throughout the study and OLE.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.1-3"></a>

###### Objective of the Part A interim analysis

> “Here, we present an interim analysis of the CAPTIVATE study, a global, multicenter, randomized, double-blind, placebo-controlled phase 3 study (NCT06858579) to evaluate the efficacy and safety of claseprubart in a broad population of adults with CIDP.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.1-4"></a>

###### Regulatory purpose stated by the company before the trial started

> “We believe this single, two-part, pivotal Phase 3 trial will support BLA filing in adult patients with CIDP and we anticipate initiating the trial by year-end 2024”

Source: [Dianthus Therapeutics (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-ex99_1.htm)

<a id="topic-3.1.1.1-5"></a>

###### Regulatory purpose stated by the company, November 2026

> “We believe that this single pivotal trial will support a Biologics License Application”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-02-10”
> “Primary Completion (Estimated) 2028-12-31”
> “Study Completion (Estimated) 2030-12-31”
> “First Posted 2025-03-05”
> “Last Update Posted 2026-10-28”
> “Recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 201 locations”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Birmingham, Alabama, United States, 35294”; “Phoenix, Arizona, United States, 85028”; “Scottsdale, Arizona, United States, 85251'”; “Los Angeles, California, United States, 90048”; “San Francisco, California, United States, 94109”; “San Francisco, California, United States, 94158”; “New Haven, Connecticut, United States, 06520”; “Washington D.C., District of Columbia, United States, 20007”; “Maitland, Florida, United States, 32751”; “Tampa, Florida, United States, 33620”; “Honolulu, Hawaii, United States, 96817”; “Chicago, Illinois, United States, 60611”; “Edwardsville, Illinois, United States, 62025”; “Indianapolis, Indiana, United States, 46202”; “Kansas City, Kansas, United States, 66160”; “Burlington, Massachusetts, United States, 01805”; “East Lansing, Michigan, United States, 48824”; “Omaha, Nebraska, United States, 68198”; “Lebanon, New Hampshire, United States, 03766”; “New York, New York, United States, 10021”; “New York, New York, United States, 10032”; “Cincinnati, Ohio, United States, 45219”; “Columbus, Ohio, United States, 43221”; “Portland, Oregon, United States, 97239”; “Nashville, Tennessee, United States, 37232”; “Dallas, Texas, United States, 75243”; “Denton, Texas, United States, 76208”; “Houston, Texas, United States, 77030”; “Houston, Texas, United States, 77054”; “Round Rock, Texas, United States, 78681”; “Sugar Land, Texas, United States, 77478”; “Seattle, Washington, United States, 98195” |
| Argentina | “Buenos Aires, Buenos Aires, Argentina”; “Rosario, Santa Fe Province, Argentina”; “Buenos Aires, Argentina”; “San Miguel de Tucumán, Argentina” |
| Australia | “Liverpool, New South Wales, Australia”; “Randwick, New South Wales, Australia, 2031”; “Saint Leonards, New South Wales, Australia, 2065”; “Sydney, New South Wales, Australia, 2033”; “Southport, Queensland, Australia, 4215”; “Melbourne, Victoria, Australia, 3004” |
| Belgium | “Anderlecht, Brussels Capital, Belgium”; “Brussels, Belgium” |
| Brazil | “Rio de Janeiro, Rio de Janeiro, Brazil, 20551-030”; “Campinas, São Paulo, Brazil”; “Belo Horizonte, Brazil, 30130-100”; “Natal, Brazil”; “Porto Alegre, Brazil, 90610-000”; “Salvador, Brazil, 40290-000”; “São Paulo, Brazil, 04038”; “São Paulo, Brazil, 05403-000”; “São Paulo, Brazil” |
| Bulgaria | “Sofia, Bulgaria” |
| China | “Hefei, Anhui, China, 230001”; “Guangzhou, Guangdong, China, 510080”; “Changsha, Hu'Nan, China, 410008”; “Changsha, Hu'Nan, China, 410013”; “Chifeng, Inner Mongolia, China, 024050”; “Suzhou, Jiangsu, China, 215006”; “Beijing, China, 100034”; “Beijing, China, 100191”; “Chengdu, China, 610072”; “Fujian, China, 350001”; “Guangdong, China, 510180”; “Guangzhou, China, 510515”; “Jilin City, China, 130021”; “Shanghai, China, 200031”; “Shanghai, China, 200040”; “Sichuan, China, 610072”; “Taiyuan, China”; “Wuhan, China” |
| Colombia | “Medellín, Antioquia, Colombia”; “Antioquia, Colombia”; “Medellín, Colombia” |
| Croatia | “Osijek, Croatia” |
| Denmark | “Aarhus, Denmark, 8200”; “Copenhagen, Denmark” |
| Eswatini | “Ulm, Eswatini, 89081” |
| France | “Bordeaux, France, 33000”; “Brest, France, 29200”; “Bron, France, 69500”; “Clermont-Ferrand, France, 63000”; “Libourne, France, 33500”; “Marseille, France, 13005”; “Nice, France, 06000”; “Paris, France, 75013”; “Paris, France, 75610”; “Strasbourg, France, 67200”; “Tours, France, 37000” |
| Georgia | “Tbilisi, Georgia” |
| Germany | “München, Bavaria, Germany”; “Sande, Lower Saxony, Germany, 26452”; “Aachen, Germany, 52074”; “Greifswald, Germany, 17489”; “Rüdersdorf, Germany, 15562”; “Sande, Germany, 26452” |
| Israel | “Beersheba, Israel”; “Haifa, Israel, 3109601”; “Safed, Israel” |
| Italy | “Bergamo, Italy, 24127”; “Bologna, Italy, 40139”; “Genova, Italy, 16132”; “Gussago, Italy, 25064”; “Milan, Italy, 20126”; “Milan, Italy, 20132”; “Milan, Italy”; “Modena, Italy”; “Monza, Italy, 20900”; “Pavia, Italy, 27100”; “Ponderano, Italy, 13875”; “Roma, Italy, 00128”; “Roma, Italy, 00133”; “Roma, Italy, 00189”; “Roma, Italy”; “Salerno, Italy, 84131”; “Terni, Italy” |
| Japan | “Niigata, Chubu, Japan”; “Kawasaki, Kanto, Japan”; “Tsukuba, Kanto, Japan”; “Kurashiki, Okayama-ken, Japan, 701-0192”; “Hirakata, Osaka, Japan”; “Kawagoe, Saitama, Japan”; “Ube, Yamaguchi, Japan, 755-0046”; “Chiba, Japan, 260-8677”; “Kyoto, Japan, 606-8507”; “Nagoya, Japan, 466-8560”; “Sapporo, Japan, 060-8556”; “Tokyo, Japan, 152-8550”; “Tokyo, Japan” |
| Latvia | “Riga, Latvia, LV-1002”; “Riga, Latvia, LV-1024” |
| Malaysia | “Kota Kinabalu, Sabah, Malaysia”; “Serdang, Salangor, Malaysia”; “Kuching, Sarawak, Malaysia”; “George Town, Malaysia, 11700”; “Johor Bahru, Malaysia, 80100”; “Kota Kinabalu, Malaysia”; “Kuala Lumpur, Malaysia, 50586”; “Kuala Lumpur, Malaysia, 50603”; “Kuala Lumpur, Malaysia, 56000”; “Kuching, Malaysia”; “Serdang, Malaysia, 43400”; “Sungai Buloh, Malaysia” |
| Netherlands | “Amsterdam, Netherlands”; “Utrecht, Netherlands” |
| North Macedonia | “Skopje, North Macedonia, 1000” |
| Philippines | “Batangas, Philippines”; “Cebu City, Philippines”; “City of Muntinlupa, Philippines”; “Iloilo City, Philippines” |
| Poland | “Bydgoszcz, Poland, 85-090”; “Krakow, Poland, 30-688”; “Lodz, Poland, 90-324”; “Lublin, Poland, 20-701”; “Lublin, Poland, 20-718”; “Lublin, Poland, 7763138”; “Warsaw, Poland, 04-141”; “Wroclaw, Poland, 50-367” |
| Romania | “Bucharest, Romania, 050474”; “Târgu Mureş, Romania, 540136” |
| Serbia | “Belgrade, Serbia, 11000”; “Kragujevac, Serbia, 34000”; “Niš, Serbia, 18000” |
| South Korea | “Daegu, South Korea”; “Daejeon, South Korea”; “Seoul, South Korea”; “Uijeongbu-si, South Korea”; “Yangsan, South Korea” |
| Spain | “Barcelona, Barcelona, Spain, 08916”; “Alicante, Spain, 03010”; “Barcelona, Spain, 08025”; “Barcelona, Spain, 08041”; “Bilbao, Spain, 48013” |
| Thailand | “Bangkok, Thailand, 10400”; “Bangkok, Thailand”; “Chiang Mai, Thailand, 50200”; “Hat Yai, Thailand”; “Khlong Luang, Thailand”; “Khon Kaen, Thailand, 40002”; “Khon Kaen, Thailand” |
| Turkey (Türkiye) | “Ankara, Turkey (Türkiye), 06230”; “Bursa, Turkey (Türkiye)”; “Istanbul, Turkey (Türkiye)”; “Samsun, Turkey (Türkiye)”; “Zeytinburnu, Turkey (Türkiye), 34010” |
| United Kingdom | “Manchester, England, United Kingdom”; “Oxford, United Kingdom” |
| Vietnam | “Hanoi, Vietnam” |

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.2-4"></a>

###### Sites activated as of September 2026

> “As of September 2026, 199 sites activated across 30 countries”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.2-5"></a>

###### Regions enrolling participants

> “CAPTIVATE was launched in 2024 and is actively enrolling participants in North America, South America, Europe, and Asia.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.2-6"></a>

###### Initiation announced by the company, March 2025

> “We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP”
> “The CAPTIVATE trial is a single, global, two-part, randomized withdrawal Phase 3 trial in patients with CIDP”

Source: [Dianthus Therapeutics (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-ex99_1.htm)

<a id="topic-3.1.1.2-7"></a>

###### Data cut-off of the interim responder analysis

> “CAPTIVATE Interim Analysis data cut off as of March 4, 2026”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.2-8"></a>

###### Timing guidance after the interim responder analysis, March 2026

> “Provide CAPTIVATE Part B top-line guidance by the end of 2026.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-3.1.1.2-9"></a>

###### Expected timing of Part A and Part B top-line results, November 2026

> “Top-line results from all participants completing Part A of this trial are expected by the end of 2027, and top-line results from Part B of this trial are expected by the end of 2028.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.2-10"></a>

###### Member states, start date, and estimated end dates in the EU trial record

> “Locations Romania, Germany, Poland, Bulgaria, Latvia, Denmark, France, Netherlands, Belgium, Italy, Croatia, Spain”
> “Start of trial 04/08/2025”
> “Estimated recruitment start date in EU/EEA: 01/09/2025”
> “Estimated end of trial date in EU/EEA: 31/12/2030”

Source: [EU Clinical Trials Information System 2024-517529-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-517529-26-00)

<a id="topic-3.1.1.2-11"></a>

###### Status by member state in the EU trial record

> “Belgium Ongoing, recruiting”
> “Denmark Ongoing, recruiting”
> “Netherlands Ongoing, recruiting”
> “Latvia Authorised, recruitment pending”
> “France Ongoing, recruiting”
> “Italy Ongoing, recruiting”
> “Germany Ongoing, recruiting”
> “Croatia Authorised, recruitment pending”
> “Bulgaria Ongoing, recruiting”
> “Spain Ongoing, recruiting”
> “Poland Ongoing, recruiting”
> “Romania Authorised, recruiting”

Source: [EU Clinical Trials Information System 2024-517529-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-517529-26-00)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Study periods and design details in the ClinicalTrials.gov record

> “The study includes the following periods: Part A: An open-label period (up to 13 weeks) Part B: A randomized, placebo-controlled, double-blind treatment period (up to 52 weeks) for participants who respond to DNTH103 in Part A Optional open-label extension (OLE) for eligible participants (up to 104 weeks) Safety follow-up (40 weeks)”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Triple (ParticipantInvestigatorOutcomes Assessor)”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.3-2"></a>

###### Two-part design described by the investigators

> “Part A is a 13-week open-label period in which patients are administered SC 300mg claseprubart Q2W for 13 weeks following an IV loading dose (Figure 2).”
> “Beginning at Week 5, patients will be assessed for a response, defined as a ≥1 point decrease in the adjusted INCAT (Inflammatory Neuropathy Cause and Treatment) score compared to Part A baseline. If the response is confirmed at the next consecutive visit, the participant will enter Part B (if the patient continues to meet the definition for response at Day 1 Part B). Non-responders will enter the safety follow-up.”
> “Part B is a randomized, placebo-controlled, double-blind treatment period of up to 52 weeks for participants who respond to claseprubart in Part A.”
> “Patients who complete Part B are permitted to enter a 104-week open-label extension (OLE).”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.3-3"></a>

###### Confirmation window, exit rules, and extension

> “Responders eligible for randomization to Part B upon confirmation beginning at Week 7 through Week 13”
> “Non-responders transition to 40-week safety follow-up”
> “Participants exit Part B upon relapse or completion”
> “Eligible participants may enter an optional open-label extension for up to 2 years”
> “No requirement for washout or deterioration”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.3-4"></a>

###### Randomized-withdrawal design described by the company

> “The CAPTIVATE trial is a single, two-part, randomized withdrawal global Phase 3 trial of claseprubart in patients with CIDP.”
> “Part A included an interim responder analysis of the first 40 participants to complete Part A.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.3-5"></a>

###### Original design before the interim responder analysis

> “Claseprubart 300mg/2mL S.C. Q2W (N= up to 480)”
> “Dosing: I.V. loading dose followed by 300mg/2mL S.C. Q2W in Part A; followed by 300mg/2mL or 600mg/4mL or placebo in Part B”
> “Responders Randomized 1:1:1 to Part B”
> “Single pivotal two-part, randomized withdrawal, double-blind, placebo-controlled trial designed to support BLA in adult patients with CIDP”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.3-6"></a>

###### Design changes announced in March 2026: Part A up to 256 participants and 600 mg arm removed from Part B

> “Maintain the claseprubart 300mg/2mL S.C. Q2W dose in Part A;”
> “Engage with regulators to remove the claseprubart 600mg/4mL S.C. Q2W arm from Part B;”
> “Enroll up to 256 patients (previously up to 480) in Part A to randomize 128 patients in Part B (previously 192); and”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-3.1.1.3-7"></a>

###### Basis for the March 2026 design changes

> “Up to 480 patients, conservative 40% minimum responder rates”
> “Up to 256 patients, conservative 50% minimum responder rates”
> “~1/3 fewer total patients anticipated in Part B and potential faster execution to top-line results”
> “Planned changes pending regulatory approval.”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.3-8"></a>

###### Design changes restated in the first quarter 2026 report, May 2026

> “In March 2026, we announced that we achieved our target of 20 confirmed responders in Part A early, with less than 40 participants completing Part A, which supported our plan to maintain the claseprubart 300mg/2mL S.C. Q2W dose in Part A; engage with regulators to remove the claseprubart 600mg/4mL S.C. Q2W arm from Part B; and enroll up to 256 patients (previously up to 480) in Part A to randomize 128 patients in Part B (previously 192).”

Source: [Dianthus Therapeutics Form 10-Q (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm)

<a id="topic-3.1.1.3-9"></a>

###### Revised design presented in June 2026

> “Revised CAPTIVATE study design going forward”
> “Responders Randomized 1:1 to Part B”
> “Ratio from Part A to Part B changed due to responder rates seen across all patient groups”

Source: [Dianthus Therapeutics presentation (2026d)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm)

<a id="topic-3.1.1.3-10"></a>

###### Part A resized to fewer than 200 participants, November 2026

> “In November 2026, we announced that the CAPTIVATE trial is now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.3-11"></a>

###### Current design presented in November 2026

> “Part A projected to require <200 participants (previously up to 256) in order to randomize 128 responders into Part B”
> “Actual Part A enrollment is subject to Part A response rate.”
> “Only responders from Part A randomized into the double-blind, placebo-controlled Part B”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.3-12"></a>

###### Differences from the ADHERE design stated by the company

> “No requirement for IVIg withdrawal and disease worsening, consistent with ongoing FcRn and complement CIDP studies”
> “ADHERE required discontinuation of IVIg or SCIg and evidence of clinically meaningful deterioration before dosing in Part A.”
> “Immediate switch 7 days from last Ig dose to claseprubart; consistent with other ongoing complement CIDP studies”
> “Data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Weight range between 40 kilograms (kg) and 120 kg.”
> “Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel.”
> “CIDP Disease Activity Status (CDAS) score ≥ 3 at screening.”
> “Must be neurologically stable.”
> “Must have an INCAT score between 2 and 9 inclusive.”
> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.”
> “18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.4-2"></a>

###### Prior treatment conditions in the ClinicalTrials.gov record

> “Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids.”
> “Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.”
> “Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and/or oral corticosteroids (defined as no clinically meaningful improvement after a period of a minimum of 12 weeks, which may include both active treatment and observation to assess response), or who at any time were unable to tolerate these treatments, experienced adverse effects, or have documented contraindications.”
> “Treatment naïve with no history of prior treatment for CIDP.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP.”
> “Known evidence of central demyelination or known history of myelopathy.”
> “Known complement deficiency or history of positive titer for anti-C1 antibodies.”
> “Diagnosis of systemic lupus erythematosus (SLE) or family history of SLE (defined as a parent, sibling, or child).”
> “Participants with an autoimmune disease affecting joints, muscle or nervous system.”
> “Any coexisting or overlapping condition, which may interfere with outcome assessments, such as severe diabetic neuropathy, fibromyalgia, inflammatory arthritis or osteoarthritis affecting the hands and feet.”
> “Prior history of N. meningitidis infection.”
> “Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.4-4"></a>

###### Study population described by the investigators

> “Adults aged 18–75 years (inclusive) with a diagnosis of CIDP or possible CIDP per the 2021 EAN/PNS guidelines.”
> “At screening, patients must have a CIDP Disease Activity Status (CDAS) score ≥3, and INCAT score between 2 and 9 (inclusive) and be neurologically stable.”
> “Patients on prior standard of care (SoC) therapy were eligible if they are SoC-refractory (worsening or inadequate response to SoC) or SoC-treated (current or past treatment with SoC).”
> “For patients on IV or SC Ig, the last dose for both must occur 1 week prior to Day 1 of Part A. Patients who received complement inhibitors or anti-CD20 treatments within the previous 6 months are not eligible.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.4-5"></a>

###### Antinuclear antibody screening removed

> “No ANA screening exclusion criteria or routine ANA testing during the RCT or OLE”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”
> “Claseprubart SC once every 2 weeks for up to 52 weeks.”
> “Placebo SC once every 2 weeks for up to 52 weeks.”
> “Claseprubart SC once every 2 weeks for up to 104 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.5-2"></a>

###### Part B randomization and dose

> “Approximately 128 participants identified as responders in Part A will be randomized 1:1 in Part B to receive 300mg claseprubart or placebo given SC once every 2 weeks.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.5-3"></a>

###### Part B arms before and after the March 2026 design change

> “300mg/2mL Q2W (N=64) 600mg/4mL Q2W (N=64) Placebo (N=64) Total Part B Patients (N=192)”
> “300mg/2mL Q2W (N=64) Placebo (N=64) Total Part B Patients (N=128)”
> “No change to Part A dose given results observed to date”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.5-4"></a>

###### Switch from prior therapy and concomitant treatment

> “Last dose of Ig and tapering of steroids completed 1 week prior to switching to claseprubart”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

> “If applicable, oral corticosteroids (after tapering) and allowed immunosuppressants are continued in Parts A and B.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.5-5"></a>

###### Rescue therapy after relapse in Part B

> “Additionally, patients who have a relapse in Part B (increase of ≥1 point in adjusted INCAT score) are also eligible for the OLE, including those who received Ig, corticosteroid, or PLEX rescue therapy.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.5-6"></a>

###### Intravenous loading dose amount

No evidence found.

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Adjusted INCAT Disability Score Relapse as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary outcome in the ClinicalTrials.gov record

> “Part B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)”
> “Adjusted INCAT scores range from 0-10 with a score of 10 indicating the greatest degree of disability. A relapse is defined as an increase of ≥1 point from baseline in adjusted INCAT score.”
> “Part B baseline to Part B end of treatment period (up to Week 52)”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.6.1-2"></a>

###### Part A response criterion

> “The primary endpoint in Part A is response as measured as ≥1 point decrease (improvement) in adjusted INCAT score compared to Part A baseline.”
> “The primary endpoint in Part B is efficacy (time to relapse) as measured as ≥1 point increase in adjusted INCAT.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

> “Responders identified by a clinically- meaningful improvement of at least 1-point in INCAT with rigorous confirmation at the following part A visit.”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.6.1-3"></a>

###### Secondary outcomes in the ClinicalTrials.gov record

> “Part B: Time to Decrease of ≥ 4 Points (Centile Metric) in Inflammatory Rasch-built Overall Disability Scale (I-RODS) Score”
> “The I-RODS score ranges from 0-100, with lower scores indicating the greatest degree of disability.”
> “Part B: Time to Decrease of ≥ 8 kilopascal (kPa) in Grip Strength in the Dominant Hand”
> “This is measured with a handheld device called a vigorimeter.”
> “Part B: Percentage of Participants who Relapse as Assessed by the Adjusted INCAT”
> “Part A: Percentage of Participants with a Confirmed Response to DNTH103 as Assessed by the Adjusted INCAT”
> “Parts A and B: Change in Medical Research Council Sum Score (MRC-SS)”
> “Parts A and B: Change in Euro-Quality of Life Visual Analogue Scale (EQ-VAS)”
> “Parts A and B: Change in Fatigue Severity Scale (FSS)”
> “Parts A, B, OLE, and Safety Follow-up: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)”
> “Parts A, B, OLE, and Safety Follow-up: Serum Concentrations of DNTH103”
> “Parts A, B, and OLE: Change from Baseline in Complement Total Blood Test (CH50)”
> “Parts A, B, OLE, and Safety Follow-up: Incidence and Titer of Antidrug Antibodies (ADAs)”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.6.1-4"></a>

###### Secondary and other assessments stated by the investigators

> “Time from first dose in Part B to a decrease from Part B baseline of ≥4 points (centile metric) in I-RODS score during Part B”
> “Time from first dose in Part B to a decrease from Part B baseline of ≥8 kPa in grip strength in the dominant hand during Part B”
> “Health-related quality of life outcomes”
> “Assess effect of claseprubart on biomarkers of disease activity”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.6.1-5"></a>

###### Adjusted INCAT disability score: definition and range

> “The adjusted INCAT score is applied throughout the study because changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 are not considered by regulatory agencies to be clinically significant in all patients”
> “The INCAT disability scale ranges from 0 (healthy) to 10 (unable to make any purposeful movements with arms or legs)”

Source: [van Schaik et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4960813/)

<a id="topic-3.1.1.6.1-6"></a>

###### Minimal clinically important difference of the adjusted INCAT disability score

> “The results demonstrated that the MCID of the primary outcome measure, the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale, was between 0.60 and 0.72. These results, therefore, provided retrospective justification for use of the applicable cut-off of 1-point on the INCAT scale to define improvement in the ICE Trial and brings support for its continuing use in CIDP trials to this day.”
> “Despite these issues, MCIDs for disability measures such as INCAT, ONLS, and I-RODS have demonstrated their value through validity and clinical relevance, making them suitable for both research and clinical practice.”

Source: [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)

<a id="topic-3.1.1.6.1-7"></a>

###### Use of the one-point adjusted INCAT threshold across CIDP trials

> “13 (72.2%) used the adjusted INCAT, in all cases with a cut-off of one point in keeping with the originally derived clinically applicable result.”
> “The ONLS scale, closely related to the INCAT, was used in one study (5.6%).”

Source: [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)

<a id="topic-3.1.1.6.1-8"></a>

###### Adjusted INCAT endpoints in earlier CIDP maintenance trials

> “The primary outcome was the percentage of patients who had maintained an improvement from baseline in adjusted INCAT disability score of 1 point or more through to week 24.”
> “During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).”

Source: [Hughes et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18178525/)

> “CIDP relapse is defined as a deterioration (i.e., increase) by at least 1 point in the total adjusted INCAT score during the SC treatment period visit compared with baseline.”

Source: [van Schaik et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4960813/)

> “The primary endpoint in stage B, evaluated in the modified intention-to-treat population, was the risk of relapse (time to first aINCAT increase of ≥1 points).”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

<a id="topic-3.1.1.6.1-9"></a>

###### Endpoint and design rationale stated by the company and investigators

> “≥1-point aINCAT improvement used as efficacy measure in ongoing studies”
> “No requirement for disease worsening in ongoing complement trials”

Source: [Dianthus Therapeutics presentation (2026d)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm)

> “CAPTIVATE features a relapse- prevention design, commonly used in studies of interventions in CIDP.”
> “CAPTIVATE prioritizes patient safety, avoids complete washout of standard of care, minimizes exposure to ineffective therapy, and provides continued access as part of an optional open-label extension.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.6.1-10"></a>

###### Measurement properties and limitations of the INCAT disability score

> “It is used frequently as a primary endpoint in inflammatory polyneuropathy clinical trials.”
> “Strengths of the INCAT score include evaluation of upper and lower limb dysfunction, ease of administration (feasibility), high face validity, and high reliability. Weaknesses of the scale include concerns about methodological quality of validation studies; failure to properly capture activity limitations due to proximal arm weakness, or fatigue; heavy individual item weighting; and poor sensitivity for detection of clinically important change.”

Source: [Breiner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24723454/)

<a id="topic-3.1.1.6.1-11"></a>

###### Inflammatory Rasch-built Overall Disability Scale secondary endpoint: development and responsiveness

> “The R-ODS is a linearly weighted scale that specifically captures activity and social participation limitations in patients with GBS, CIDP, and MGUSP.”

Source: [van Nes et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21263135/)

> “The I-RODS more often captures clinically meaningful changes over time, with a greater magnitude of change, compared with the INCAT-ONLS disability scale in patients with GBS and CIDP.”

Source: [Draak et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25378677/)

> “The summed raw score will subsequently be transformed to a centile score that ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).”

Source: [van Schaik et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4960813/)

<a id="topic-3.1.1.6.1-12"></a>

###### Inflammatory Rasch-built Overall Disability Scale threshold of 4 centile points

> “Ten studies (55.6%) used the I-RODS, some with multiple MCIDs, of which 3/10 set the cut-off at 4 centile points and another 3/10 at 4 raw points.”
> “Of note, no justification for use of an I-RODS MCID of 4 centile points could be found through previous or per-study derivation, including in the recent ADHERE trial where it was nevertheless used.”

Source: [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)

<a id="topic-3.1.1.6.1-13"></a>

###### Grip strength secondary endpoint: Vigorimeter validity and the 8 kPa threshold

> “Good interobserver and intra-observer agreements (analysis of variance, r = 0.95-0.97) and high responsiveness (standardized response mean scores > or = 0.8) were demonstrated for the Vigorimeter.”

Source: [Merkies et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10951442/)

> “A minimum clinically important difference cut-off value for grip strength (>8 kPa) and INCAT score (>1 point) was applied to assess the proportion of responders to IGIV-C versus placebo.”
> “Grip strength can be considered a sensitive tool for assessing clinically relevant changes in patients with CIDP.”

Source: [Vanhoutte et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22891893/)

> “MCID discrepancies between ascertainment methods were, on the other hand, found for grip strength (14 kPa with the anchor-based method vs. 8 kPa using ½ SD or SE)”
> “Eleven studies (61.1%) used grip strength through Martin vigorimeter readings with an MCID cut-off exclusively of 8 kPa in 9/11”

Source: [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)

<a id="topic-3.1.1.6.1-14"></a>

###### Outcome measure thresholds in the 2021 EAN/PNS guideline, as reviewed

> “A short list of outcome measures with cut-offs, in some cases variable, was provided as a guide. The list was mainly based on previous MCID utilization in trials and not consistently obtained from previous studies of clinically- or research-derived cut-offs.”

Source: [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)

<a id="topic-3.1.1.6.1-15"></a>

###### Changes used to define improvement on disability and impairment scales in the 2021 EAN/PNS guideline

> “Objective response to treatment requires improvement on at least one disability and one impairment scale.”
> “The changes required to define improvement have not been adequately validated. The following which have been used in clinical trials can serve as a guide:”
> “I-RODS: + ≥4 centile points”
> “INCAT disability scale: − ≥1 point”
> “MRC sum score (0-60): + ≥2 to 4 points”
> “Grip strength: Martin Vigorimeter: + ≥8 to 14 kPa”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Estimated enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 256”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned numbers stated by the investigators, June 2026

> “It is anticipated that approximately 256 participants will be enrolled into Part A. An interim responder analysis was planned with the first 40 patients completing Part A.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned numbers, November 2026

> “Phase 3 CAPTIVATE trial of claseprubart in CIDP evaluating 300mg/2mL Q2W now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-3.1.1.7.1-4"></a>

###### Interim responder analysis size and decision criterion

> “The target for the Part A interim responder analysis was a response rate of 50% or greater (i.e., ≥20 confirmed responders out of first 40 participants to complete Part A) based on precedent set with aC1s inhibition.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

> “GO: However, increase dose as responder rate below precedent”
> “GO: Keep dose 300mg/2mL Q2W as target responder rate met or exceeded”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants analyzed in the interim analysis

> “The pre-planned Part A interim analysis included the first 40 claseprubart-treated patients with evaluable efficacy data.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.7.1-6"></a>

###### Sample size calculation for Part B

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Interim analysis set

> “An interim futility analysis was conducted on the first 40 patients who completed Part A with evaluable efficacy.”
> “Data are from per protocol interim analysis from first 40 participants to complete Part A with evaluable efficacy data. Responder defined as achieving ≥1 point decrease in the adjusted INCAT. Non-responders include relapses and stable patients.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.7.2-2"></a>

###### Last evaluable visit used for change from baseline

> “Last Evaluable Visit: for confirmed responders signifies last visit prior to randomization in Part B; for stable patients signifies Week 13 visit (completion of Part A); for relapse patients signifies confirmed relapse visit prior to any rescue medication.”

Source: [Dianthus Therapeutics presentation (2026d)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm)

<a id="topic-3.1.1.7.2-3"></a>

###### Analysis set for the March 2026 baseline summary

> “Includes only participants who have completed Part A. Data cut off as of March 4, 2026”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.7.2-4"></a>

###### Part B analysis populations

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Early GO decision, March 2026

> “This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing Part A of the trial.”
> “The GO decision was confirmed by an independent DSMB review.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-3.1.1.8.1-2"></a>

###### Outcome of the first 40 participants completing Part A

> “Of the 10 non-responders, five had stable CIDP and five had a relapse.”
> “Non-responders will enter the safety follow-up.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

> “75% Confirmed Responders 12.5% Non-responders with Relapse 12.5% Stable Non- responders”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.8.1-3"></a>

###### Discontinuations in the interim analysis

> “AE leading to discontinuation 0 (0)”
> “The patient continued in the study.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.1-4"></a>

###### Enrollment and randomization to Part B to date

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline demographics and disease characteristics of the interim analysis set

| Characteristic | Claseprubart 300 mg every 2 weeks (N=40) |
| --- | --- |
| Age, years, mean (SD) | “56.9 (12.5)” |
| Age, years, median (range) | “59.5 (31–74)” |
| Male, n (%) | “26 (65.0)” |
| Typical CIDP, n (%) | “35 (87.5)” |
| Multifocal CIDP, n (%) | “2 (5.0)” |
| Motor CIDP, n (%) | “3 (7.5)” |
| Mean time since diagnosis, years (SD) | “4.2 (6.1)” |
| Prior treatment: SoC-treated, n (%) | “27 (67.5)” |
| Prior treatment: immunoglobulin, n (%) | “19 (47.5)” |
| Prior treatment: oral corticosteroids, n (%) | “8 (20.0)” |
| Prior treatment: SoC-refractory, n (%) | “9 (22.5)” |
| Prior treatment: treatment-naive, n (%) | “4 (10.0)” |
| INCAT, mean (SD) | “4.0 (1.21)” |
| Grip strength, kPa, mean (SD) | “41.4 (20.0)” |
| I-RODS, mean (SD) | “47.9 (13.7)” |
| MRC-SS, mean (SD) | “50.5 (5.6)” |

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline summary stated by the investigators

> “Most patients presented with typical CIDP with a mean (SD) time from diagnosis of 4.2 (6.1) years and were receiving immunoglobulins or oral corticosteroids at study entry (Table 1).”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.2-3"></a>

###### Prior treatment groups at the March 2026 data cut-off

> “~69% SoC-Treated ~19% SoC-Refractory ~12% SoC- Naïve”
> “Broad representation of patients across North America, Europe, and Asia in CAPTIVATE Part A”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.8.2-4"></a>

###### Race, ethnicity, and enrollment by region

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Confirmed response rate in the first 40 participants completing Part A

> “Seventy-five percent (n=30) of the first 40 SC Q2W 300mg claseprubart-treated patients in Part A were confirmed responders (≥1 point decrease in the adjusted INCAT) (Figure 3A).”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

> “75% of the futility cohort in open-label Part A achieved at least a 1-point confirmed INCAT response above clinical baseline on maintenance therapy with a meaningful mean improvement of 1.6”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.8.3-2"></a>

###### Response rate against the interim target, announced June 2026

> “In June 2026, we announced a 75% response rate observed in the Interim Responder Analysis from the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.”
> “The results were consistent and clinically meaningful across multiple efficacy measures.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.”

Source: [Dianthus Therapeutics (2026e)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-ex99_1.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Change from Part A baseline at the last evaluable visit, by responder status

| Measure, mean (SD) | Confirmed responders (n=30) | Non-responders (n=10) |
| --- | --- | --- |
| INCAT (decrease is improvement) | “–1.6 (0.89)” | “0.7 (1.06)” |
| Grip strength (increase is improvement) | “15.9 (12.78)” | “–7.5 (12.19)” |
| MRC-SS (increase is improvement) | “5.1 (3.93)” | “–2.3 (8.82)” |
| I-RODS (increase is improvement) | “8.9 (12.08)” | “–3.0 (10.69)” |

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.3-4"></a>

###### Secondary measures in confirmed responders

> “Confirmed responders also demonstrated clinically-meaningful improvements in grip strength, MRC-SS, and I-RODS after 13 weeks of Q2W claseprubart treatment (Figure 3B).”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

> “The INCAT response was supported by meaningful mean improvement in every secondary efficacy metric”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.8.3-5"></a>

###### Response by prior treatment group

No evidence found.

<a id="topic-3.1.1.8.3-6"></a>

###### Part B time to relapse

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Inflammatory Rasch-built Overall Disability Scale change from Part A baseline

| Measure, mean (SD) | Confirmed responders (n=30) | Non-responders (n=10) |
| --- | --- | --- |
| I-RODS (increase is improvement) | “8.9 (12.08)” | “–3.0 (10.69)” |

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.8.4-2"></a>

###### EQ-VAS and Fatigue Severity Scale results

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Adverse events in the interim analysis set

| Event, n (%) | Claseprubart 300 mg every 2 weeks (N=40) |
| --- | --- |
| Patients with any AEs | “24 (60)” |
| Grade 3 (not treatment-related) | “1 (3)” |
| Treatment-related infections | “0 (0)” |
| Patients with any SAEs | “1 (3)” |
| Treatment-related SAEs | “0 (0)” |
| Serious infections | “0 (0)” |
| AE leading to discontinuation | “0 (0)” |

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.5-2"></a>

###### Severity, serious adverse events, and discontinuations

> “Claseprubart was generally well-tolerated. All but one adverse event (AE; unrelated grade 3) were mild or moderate in severity with no treatment-related or serious infections, no related serious AEs, or discontinuations due to safety (Table 2).”
> “One grade 3 serious AE of ureterolithiasis (not treatment-related) was reported in a patient with a history of ureterolithiasis prior to enrollment. The patient continued in the study.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-3.1.1.8.5-3"></a>

###### Safety at the March 2026 GO decision

> “There have been no related serious infections, no clinical symptoms of autoimmune activation, no related serious adverse events or discontinuations.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Drug-induced lupus and serious infections, August 2026

> “Claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of drug-induced lupus (DIL), no related serious adverse events (SAEs) or discontinuations due to safety.”

Source: [Dianthus Therapeutics (2026e)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-ex99_1.htm)

<a id="topic-3.1.1.8.5-5"></a>

###### Adverse events by type

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The only CAPTIVATE results are from an interim analysis of open-label Part A: of the first 40 participants who completed Part A with evaluable efficacy data, 30 (75%) were confirmed responders in this per-protocol interim analysis, and the company describes the summaries as preliminary. Part A has no comparator arm, so the 75% response rate and the changes in grip strength, MRC-SS, and I-RODS among responders are uncontrolled. In the randomized-withdrawal design, only Part A responders enter the placebo-controlled Part B, whose primary endpoint is time to relapse (an increase of at least 1 point in adjusted INCAT); Part B results are expected by the end of 2028 and will describe participants who first responded to claseprubart. The trial was resized after the interim analysis: in March 2026 the company announced plans, pending regulatory approval, to remove the 600 mg Part B arm and to enroll up to 256 participants in Part A (previously up to 480) to randomize 128 in Part B (previously 192); the investigators later described 1:1 randomization in Part B to claseprubart 300 mg or placebo, and in November 2026 Part A was projected to require fewer than 200 participants, while the registry still lists an estimated enrollment of 256.

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3); [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b); [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-3.1.1.9-2"></a>

###### Preliminary status of the interim data

> “The summaries presented are preliminary. The study remains ongoing and the data are not final.”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-3.1.1.9-3"></a>

###### Limited disclosure to preserve trial integrity

> “This Presentation contains limited disclosure with respect to an interim responder analysis in the open-label Part A of the registrational claseprubart CAPTIVATE study. The level of detail in this Presentation is limited to preserve the integrity of the trial as a two-part registrational trial.”

Source: [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)

<a id="topic-3.1.1.9-4"></a>

###### Predictive value of the interim analysis stated by the company

> “that the preliminary interim analysis based on a limited number of patients from the Part A open-label portion”
> “of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-3.1.2"></a>

#### 3.1.2 DNTH103-AU-001

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Primary objectives in the Part A and Part B registry record

> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as multiple doses in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.1-2"></a>

###### Secondary objectives in the Part A and Part B registry record

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV or SC as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.1-3"></a>

###### Part C objectives: pharmacokinetics after human normal immunoglobulin G

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the PK of DNTH103 when administered SC following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV following administration of IgG as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV following administration of IgG as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.1-4"></a>

###### Objectives stated by the company at study start and at top-line results

> “Data from this Phase 1 study will provide important information about the safety, tolerability, pharmacokinetics and pharmacodynamics of DNTH103 in healthy adult volunteers across single and multiple ascending dose cohorts”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

> “The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registration, recruitment dates, and status of Parts A and B

> “Date registered 23/09/2022”
> “Type of registration Prospectively registered”
> “Recruitment status Completed”
> “Date of first participant enrolment Anticipated 17/11/2022 Actual 19/11/2022”
> “Date of last participant enrolment Anticipated 31/03/2024 Actual 18/03/2024”
> “Date of last data collection Anticipated 15/09/2024 Actual 6/01/2025”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.2-2"></a>

###### Study location, sponsors, and ethics committee

> “Recruitment outside Australia Country [1] New Zealand State/province [1] Christchurch”
> “Primary sponsor type Commercial sector/Industry Name Dianthus Therapeutics, Inc.”
> “Secondary sponsor category [1] Commercial sector/Industry Name [1] Avance Clinical Pty Ltd”
> “Ethics committee name [1] Southern Health and Disability Ethics Committee”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.2-3"></a>

###### Registration, recruitment dates, and status of Part C

> “Date registered 27/03/2024”
> “Type of registration Retrospectively registered”
> “This record is a sub study of ACTRN12622001265763”
> “Date of first participant enrolment Anticipated Actual 12/12/2023”
> “Date of last participant enrolment Anticipated Actual 18/03/2024”
> “Date of last data collection Anticipated Actual 6/01/2025”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.2-4"></a>

###### First participant dosed, November 2022

> “November 30, 2022 – Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead monoclonal antibody, DNTH103.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.2.2-5"></a>

###### Trial initiation and top-line data dates reported by the company

> “Ph. 1 HV trial initiated in November 2022”
> “Top-line Ph. 1 data demonstrated potent, long-acting classical pathway inhibition in August 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.2-6"></a>

###### Country of the trial

> “We conducted our Phase 1 clinical trial for claseprubart in New Zealand”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Single ascending dose and multiple ascending dose parts

> “The study will be conducted in two parts: Part A, the single ascending dose (SAD) portion, and Part B, the multiple ascending dose (MAD) portion. Participants in Part A and Part B will be distinct.”
> “Each cohort will enroll 8 participants with 6 participants randomised to receive DNTH103 and 2 participants randomised to receive placebo. The first two subjects dosed in each cohort will be considered sentinel subjects, one each receiving active study drug and placebo.”
> “The time separation between Part A and Part B is not fixed. Part B will not commence until safety at the higher dose in Part A is determined through an SRC review.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.3-2"></a>

###### Randomization and blinding of Parts A and B

> “Allocation to intervention Randomised controlled trial”
> “The allocation to DNTH103 or placebo will be performed using a block randomisation algorithm and will be documented in the study randomisation schedule.”
> “This study is a double-blind study. Those blinded to study drug assignment include the Investigator, site staff (other than pharmacists), Sponsor, the PI, clinical study personnel participating in participants’ care or clinical evaluations, and the study participants.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.3-3"></a>

###### Part C: open-label, uncontrolled single cohort

> “Part C will be open label and will not be placebo controlled.”
> “No sentinel dosing is required.”
> “Part C will be initiated after dosing and SRC review is completed for Part A cohort SAD IV4.”
> “Allocation to intervention Non-randomised trial”
> “Masking / blinding Open (masking not used)”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.3-4"></a>

###### First-in-human design described by the company

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “Body mass index less than or equal to 32 kg/m2, with a body weight (to 1 decimal place) greater than or equal to 45 kg and less than or equal to 100 kg at Screening.”
> “Medically healthy without clinically significant abnormalities (in the opinion of the Investigator) at the Screening visit and after check-in on Day -1, prior to dose administration on Day 1”
> “Previously immunized against encapsulated bacterial pathogens as per country-specific guidelines (Neisseria meningitis, Haemophilus influenza, and Streptococcus pneumonia within past 5 years) or willing and able to be vaccinated during the Screening Period and at least 14 days prior to study drug administration on Day 1.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria

> “History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within 3 months prior to screening determined by the PI to be clinically significant.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Administration of any live, attenuated vaccines within 30 days and all other vaccinations within 14 days prior to study drug administration.”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.4-3"></a>

###### Part C eligibility

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Planned Part A single-dose cohorts

> “Single dose DNTH103 or placebo administered on Day 1 (IV or SC) as follows:”
> “SAD IV1, 1 mg/kg”
> “SAD IV2, 3 mg/kg”
> “SAD IV3, 10 mg/kg”
> “SAD IV4, 30 mg/kg”
> “SAD IV5, 60 mg/kg”
> “SAD SC1, 300 mg”
> “SAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-2"></a>

###### Planned Part B multiple-dose cohorts

> “DNTH103 or placebo is scheduled to be administered at 2-week intervals on Day 1, Day 15 and Day 29 (total of three doses) as follows:”
> “MAD SC1, 300 mg”
> “MAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-3"></a>

###### Placebo comparator

> “Placebo (matching IV infusion or SC injection) and a sterile saline for IV injection, or excipient alone for SC injection.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-4"></a>

###### Dose cohorts reported as dosed

> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.5-5"></a>

###### Part C: intravenous immunoglobulin before a single dose of DNTH103

> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution:”
> “IV7, 10 mg/kg”
> “Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution:”
> “IV7, 600 mg”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary safety endpoints and adverse event grading

> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE)”
> “Incidence, severity and relationship of adverse events of special interest”
> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE) and AEs of special interest graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (Version 5).”
> “Final Safety Follow Up (determined when the participant’s CH50 level has met normalization criteria).”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.6.1-2"></a>

###### Safety as the purpose of a first-in-human study

> “This is a first in human study for DNTH103.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Claseprubart Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety”
> “Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.6.1-3"></a>

###### Infection risk with complement inhibition

> “by leaving the lectin and alternative pathways intact, the risk of infection from encapsulated bacteria is lower for DNTH103 versus commonly used C5 and C3 inhibitors.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.2.6.1-4"></a>

###### Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints

> “Maximum concentration (Cmax)”
> “Terminal elimination half-life (t½)”
> “Absolute bioavailability (Fabs)”
> “Complement system classical pathway (CP) inhibition measures in serum ex vivo by the WIESLAB® assay”
> “CH50 (complement haemolysis 50%) in serum ex vivo”
> “Incidence of anti-drug antibody (ADA) to DNTH103”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.6.1-5"></a>

###### Part C: pharmacokinetics as the primary endpoint

> “Type of endpoint/s Pharmacokinetics”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment and sample size basis in the Part A and Part B registry record

> “Part A: Up to approximately 72 participants are planned to be enrolled as follows:”
> “56 healthy volunteers will be enrolled into seven SAD cohorts, five cohorts receiving study drug as an intravenous (IV) infusion and two receiving study drug as a subcutaneous (SC) injection.”
> “Part B: Up to approximately 24 participants are planned to be enrolled as follows:”
> “As such, no formal sample size calculations have been performed. The number of participants in each treatment arm is considered sufficient to achieve the objectives of the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.7.1-2"></a>

###### Final accrual in the registry records, last updated June 2025

> “Date last updated 8/06/2025”
> “Sample size Target 96 Accrual to date Final 68”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Up to a maximum of 8 participants will be enrolled in a single cohort (IV7)”
> “Sample size Target 8 Accrual to date Final 9”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants in the top-line analysis, September 2023

> “Top-line data across seven single and multiple ascending dose cohorts with 52 healthy volunteers confirmed its approximately 60-day half-life and highly potent classical pathway inhibition”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants by part reported in January 2024

> “44 HVs enrolled into six cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “16 HVs enrolled into two cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.7.1-5"></a>

###### Participants reported in the annual report filed March 2025

> “Data from DNTH103’s Phase 1 clinical trial in 60 healthy volunteers across eight dose cohorts validates the extended half-life and potent classical pathway inhibition and supports a potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations

> “The safety population will consist of all randomised participants who received any amount of study drug. Participants will be analysed according to actual treatment received.”
> “The PK population will include all randomised participants who received treatment where there is at least one post-dose measurement of serum PK concentration data.”
> “The PD population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose PD parameter and will be analysed based on the actual treatment received.”
> “The immunogenicity population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose immunogenicity parameter, and will be analysed based on the actual treatment received.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participants who completed dosing, as of December 2023

> “In completed cohorts, 60 healthy volunteers completed dosing as of December 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “60 healthy volunteers completed dosing as of December 2023 across these eight cohorts”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.1-2"></a>

###### Completion of treatment after injection site reactions

> “No intervention was required and both participants completed treatment”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Pharmacokinetic results: half-life and dose proportionality

> “DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL”
> “I.V. SAD: Linear PK with Exposure Proportional Across Doses”
> “S.C. MAD: Strong Accumulation with Q2W Dosing”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### Pharmacodynamic results: classical pathway inhibition and simulated steady state

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL”
> “We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing”
> “600mg S.C. Q2W dosing surpasses IC95, currently calculated at 149 µg/mL”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.3-3"></a>

###### Dose selection for later trials based on phase 1 data

> “Ph. 1 data in 2023 showed potency and long half-life, and DNTH103 was generally well tolerated, allowing for 300mg/2mL Q2W S.C. dosing”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

> “Phase 1 data estimated IC90 at ~87 µg/mL, leading to target dose of 300mg/2mL in Ph. 2 to achieve steady state >IC90”
> “Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.3-4"></a>

###### Part C pharmacokinetics after immunoglobulin G

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Overall tolerability, serious adverse events, and infections

> “The results also demonstrated DNTH103 was generally well tolerated with no serious adverse events or complement-related infections.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

> “Claseprubart was generally well tolerated with no SAEs or complement-related infections.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.2.8.5-2"></a>

###### Adverse events reported across the eight cohorts

> “DNTH103 was generally well tolerated, with a favorable safety profile in Phase 1”
> “No standard safety lab findings (hematology, chemistry, coagulation LFTS and renal function)”
> “No serious adverse events”
> “No infection adverse event signal and no infections related to encapsulated bacteria”
> “Five participants experienced mild/moderate Treatment Related AEs”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Injection site reactions, infusion events, and vomiting

> “Two participants (one in each 300mg and 600mg S.C. MAD cohorts) had a mild or moderate injection site reactions (ISRs)”
> “One participant experienced several non-specific AEs during infusion; infusion was paused for 8 minutes and restarted at the same rate without sequelae”
> “One participant in 600mg S.C. SAD reported vomiting on Day 1, which resolved on same day”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-4"></a>

###### Antinuclear antibody positivity in the 50 mg/kg intravenous cohort

> “Two participants in 50mg/kg SAD I.V.1 cohort became ANA”
> “positive at Day 57; both participants had no evidence of SLE and both tested negative for dsDNA”
> “One participant subsequently tested negative for ANA in a one-month safety follow-up post Day 57”
> “Other participant experienced inflammatory arthritis and tested negative on broader autoimmune panel”
> “Non-specific indicator of autoimmune disease present in up to 25% of healthy individuals”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-5"></a>

###### Part C safety

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx); [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx); [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm); [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm); [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.2.9-2"></a>

###### Results limited to healthy volunteers and phase 1 data

> “We currently have only preclinical data and data from our Phase 1 clinical trial regarding properties of DNTH103 and the same results may not be seen in patients in our later stage trials.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.9-3"></a>

###### No results documents in the registry records

> “Documents added manually No documents have been uploaded by study researchers.”
> “Will the study consider sharing individual participant data? No”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Documents added manually No documents have been uploaded by study researchers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.9-4"></a>

###### Trial conducted outside the United States

> “Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA.”
> “The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
